Q4 2019 Imricor Medical Systems Inc Earnings Call Transcript
(technical difficulty)
Thanks, Steve. As a reminder, all numbers are unaudited and in U.S. dollars.
Net cash outflows from operating activities was $2.242 million for the fourth quarter, which was significantly higher than the third quarter as the company continued to build inventory in preparation for CE mark approval. Cash outflows from investing were $28,000. Financing cash outflows were $608,000, consisting primarily of the payment of remaining IPO transaction costs.
Our cash balance of $5.049 million was less than the prospective amount of $7.954 million due to the reductions in revenue due to the delay in CE mark, the cancellation of the NIH contract and the delay in IP license revenue. These reductions were partially offset by lower than forecast accounts receivable, inventory purchases and operational spending.
I'll hand it back over to Steve now to provide you with an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
